BPC-157

• Recovery from a tendon or joint injuryrecommended

  Community practice, not from a label or trial: the bottom of the 250-500 mcg/day, 4-12 week range. No trial supports it.

• Community practice, not from a label or trial: 250 to 500 mcg per day, one to two times daily, 3 to 5 times a week, 4 to 12 weeks (Dr Pat Taylor page). The page gives no per-injection amount, and it is a clinic information page, not a trial.
• Route in the community figure: subcutaneous near the injury site, or oral for the gut (same page).
• Human reports: the knee-injection survey did not report a dose; the IV pilot gave 10 mg then 20 mg intravenously in 250 mL saline over one hour on two days to two people (PubMed 40131143). Those are not self-dosing figures.

Route: Subcutaneous (community figure, near the injury site). Intra-articular and intravenous use appear only in small clinic reports.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Placeholder 5 mg vial plus 2 mL gives 2,500 mcg/mL, so 250 mcg is 10 units on a 100-unit syringe. This is arithmetic, not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

Community cycles are 4 to 12 weeks; no sourced rest period.

Why:

• The sources give no off-cycle figure and no long-term human safety data.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Not an FDA-approved drug. FDA removed it from the 503A Category 2 list on April 15 2026 because the nominators withdrew, which does not make it compoundable; a July 2026 advisory committee recommendation is not yet a rule. Check current status.

Common side effects:

• Injection-site reactions (10-30%), nausea and headache (1-10%) are listed by one secondary page, which says its own figures do not come from quantified adverse-event data.
• Long-term human safety is unknown; systematic adverse-event monitoring has not been done.
• Clinic pages list cancer history, pregnancy and breastfeeding, and anticoagulant use as reasons to avoid it.

Stop and call your prescriber if:

• Swelling, redness or pain spreading from the injection site
• Rash, hives or trouble breathing
• Any new unexplained symptom

No reliable source names a biomarker for this compound.

• PubMed 34324435: intra-articular BPC-157 for knee pain, retrospective review of 16 patients (2021)
• PubMed 40131143: intravenous BPC-157 safety pilot, 2 adults (2025)
• Community dose ranges (Dr Pat Taylor BPC-157 page; secondary source)
• Peptide Protocol Wiki: BPC-157 side effects and evidence gaps (secondary source)
• FDA 503A bulk drug substances categories page
• Frier Levitt: FDA removes 12 peptides from Category 2 (April 2026)
• McDermott: advisory committee backs most peptides for the 503A list (July 2026)